Peritoneal metastasiertes kolorektales Karzinom: zytoreduktive Chirurgie und hypertherme intraperitoneale Chemotherapie

Zusammenfassung

Die Peritonealkarzinose eines kolorektalen Karzinoms gilt nach wie vor als terminales Tumorstadium. Durch ein multimodales Therapiekonzept bestehend aus einer maximalen Zytoreduktion, gefolgt von einer hyperthermen intraperitonealen Chemotherapie (HIPEC), kann bei ausgewählten Patienten potenziell ein Langzeitüberleben erreicht werden. Eine ausschließlich palliative systemische Therapie bei isolierter Peritonealkarzinose entspricht somit nicht mehr modernen Gesichtspunkten. In diesem Artikel werden Aspekte der Erkrankung, die Rationale für eine Peritonektomie mit HIPEC und das chirurgische Vorgehen der Peritonealkarzinose beleuchtet.

Abstract

Peritoneal carcinomatosis caused by colorectal carcinoma is still considered as the end-stage of disease. A multi-modal therapeutic concept including maximal cytoreduction followed by intraperitoneal hyperthermic chemotherapy (HIPEC) has the potential to cure selected patients. In case of peritoneal carcinomatosis palliative systemic treatment is no longer the state of the art. This article addresses aspects of the disease, the rationale behind peritonectomy with HIPEC, and the surgical management of peritoneal carcinomatosis.

Schlüsselwörter

Peritonealkarzinose - kolorektales Karzinom - Peritonektomie - hypertherme intraperitoneale Chemotherapie (HIPEC)

Keywords

peritoneal carcinomatosis - colorectal carcinoma - peritonectomy - hyperthermic intraperitoneal chemotherapy (HIPEC)

Literatur

• 1 Chua T C, Saxena A, Schellekens J F. et al . Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment.  Ann Surg. 2010;  251 101-106
• 2 Chua T C, Yan T D, Zhao J, Morris D L. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection.  Eur J Surg Oncol. 2009;  35 1299-1305
• 3 da Silva R G, Sugarbaker P H. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.  J Am Coll Surg. 2006;  203 878-886
• 4 Elias D, Lefevre J H, Chevalier J. et al . Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.  J Clin Oncol. 2009;  27 681-685
• 5 Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, Malka D, Pignon J P, Lasser P. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect.  Ann Surg Oncol. 2005;  12 900-909
• 6 Elias D, Gilly F, Boutitie F. et al . Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.  J Clin Oncol. 2010;  28 63-68
• 7 Elias D, Benizri E, Pocard M. et al . Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer.  Eur J Surg Oncol. 2006;  32 632-636
• 8 Elias D, Raynard B, Farkhondeh F. et al . Peritoneal carcinomatosis of colorectal origin.  Gastroenterol Clin Biol. 2006;  30 1200-1204
• 9 Elias D M. Peritoneal carcinomatosis or liver metastases from colorectal cancer: similar standards for a curative surgery?.  Ann Surg Oncol. 2004;  11 122-123
• 10 Elias D, Goere D, Di Pietrantonio D. et al . Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis.  Ann Surg. 2008;  247 445-450
• 11 Evers D J, Verwaal V J. Indication for oophorectomy during cytoreduction for intraperitoneal metastatic spread of colorectal or appendiceal origin.  Br J Surg. 2011;  98 287-292
• 12 Jayne D G, Fook S, Loi C. et al . Peritoneal carcinomatosis from colorectal cancer.  Br J Surg. 2002;  89 1545-1550
• 13 Pfannenberg C, Königsrainer I, Aschoff P. et al . (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.  Ann Surg Oncol. 2009;  16 1295-1303
• 14 Ripley R T, Davis J L, Kemp C D, Steinberg S M, Toomey M A, Avital I. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.  Trials. 2010;  11 62
• 15 Sugarbaker P H. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis.  Semin Surg Oncol. 1998;  14 254-261
• 16 Sugarbaker P H. Peritonectomy procedures.  Ann Surg. 1995;  221 29-42
• 17 Sugarbaker P H, Cunliffe W J, Beliveau J F. et al . Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy.  Reg Cancer Treatment. 1988;  1 66-79
• 18 Van der Speeten K, Stuart O A, Chang D, Mahteme H, Sugarbaker P H. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.  Cancer Chemother Pharmacol. 2011;  68 147-156
• 19 Verwaal V J, van Ruth S, de Bree E. et al . Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.  J Clin Oncol. 2003;  21 3737-3743
• 20 Verwaal V J, van Ruth S, Witkamp A. et al . Long-term survival of peritoneal carcinomatosis of colorectal origin.  Ann Surg Oncol. 2005;  12 65-71
• 21 Verwaal V J, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.  Ann Surg Oncol. 2008;  15 2426-2432
• 22 Yan T D, Morris D L. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?.  Ann Surg. 2008;  248 829-835
• 23 Zieker D, Königsrainer I, Weinreich J. et al . Phosphoglycerate kinase 1 promoting tumor progression and metastasis in gastric cancer – detected in a tumor mouse model using positron emission tomography/magnetic resonance imaging.  Cell Physiol Biochem. 2010;  26 147-154
• 24 Zieker D, Königsrainer I, Tritschler I. et al . Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer.  Int J Cancer. 2010;  15, 126 1513-1520
• 25 Zieker D, Königsrainer I, Traub F. et al . PGK1 a potential marker for peritoneal dissemination in gastric cancer.  Cell Physiol Biochem. 2008;  21 429-436